{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:24:39Z","timestamp":1794003879510,"version":"4.8.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ijgc.2026.104881","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:22:40Z","timestamp":1785770560000},"page":"104881","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hormone replacement therapy in gynecologic cancer survivors: bridging the gap between evidence and clinical practice"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0361-8741","authenticated-orcid":false,"given":"Blanca","family":"Gil-Ib\u00e1\u00f1ez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6007-0308","authenticated-orcid":false,"given":"Ana","family":"Luzarraga Aznar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0074-6614","authenticated-orcid":false,"given":"M. Pilar","family":"Barretina-Ginesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuri","family":"Quer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro T.","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1016\/j.ijgc.2026.104881_bib1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/ijgo.70279","article-title":"Global determinants of gynecologic cancer incidence and mortality: a cluster-based analysis with predictive insights","volume":"171","author":"Cuello","year":"2025","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ijgc.2026.104881_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102713","article-title":"Global, regional, and national burden of female cancers in women of child-bearing age, 1990-2021: analysis of data from the global burden of disease study 2021","volume":"74","author":"Sun","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"10430","key":"10.1016\/j.ijgc.2026.104881_bib3","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S0140-6736(23)02802-7","article-title":"Managing menopause after cancer","volume":"403","author":"Hickey","year":"2024","journal-title":"Lancet."},{"key":"10.1016\/j.ijgc.2026.104881_bib4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.maturitas.2020.01.005","article-title":"European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis","volume":"134","author":"Rees","year":"2020","journal-title":"Maturitas"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104881_bib5","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2024.35.e70","article-title":"Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey","volume":"35","author":"Palaia","year":"2024","journal-title":"J Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104881_bib6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104881_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/clinem\/dgaa764","article-title":"The menopause transition: signs, symptoms, and management options","volume":"106","author":"Santoro","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104881_bib8","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ygyno.2021.10.001","article-title":"Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study","volume":"163","author":"Gernier","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"24","key":"10.1016\/j.ijgc.2026.104881_bib9","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.3390\/cancers17244022","article-title":"Insomnia in women surviving breast and gynecological cancers-a narrative review to address the hormonal factor","volume":"17","author":"Martella","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104881_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ajog.2019.08.043","article-title":"Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy","volume":"222","author":"Crean-Tate","year":"2020","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104881_bib11","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s00404-020-05896-6","article-title":"Cancer-related cognitive impairment (CRCI), depression and quality of life in gynecological cancer patients: a prospective study","volume":"303","author":"De Rosa","year":"2021","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104881_bib12","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ygyno.2010.06.023","article-title":"Cognitive functions in long-term survivors of ovarian cancer","volume":"119","author":"Correa","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"24","key":"10.1016\/j.ijgc.2026.104881_bib13","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.2019.19191","article-title":"Association of premature natural and surgical menopause with incident cardiovascular disease","volume":"322","author":"Honigberg","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ijgc.2026.104881_bib14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.maturitas.2022.06.011","article-title":"Increased mortality and non-cancer morbidity risk may be associated with early menopause and varies with aetiology: an exploratory population-based study using data-linkage","volume":"164","author":"Thong","year":"2022","journal-title":"Maturitas"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104881_bib15","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/humrep\/dead130","article-title":"Age at menopause and all-cause and cause-specific dementia: a prospective analysis of the UK Biobank cohort","volume":"38","author":"Hao","year":"2023","journal-title":"Hum Reprod"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104881_bib16","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.annonc.2022.05.009","article-title":"Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Oaknin","year":"2022","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104881_bib17","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/20533691241286666","article-title":"British Gynaecological Cancer Society and British Menopause Society guidelines: management of menopausal symptoms following treatment of gynaecological cancer","volume":"30","author":"Taylor","year":"2024","journal-title":"Post Reprod Health"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104881_bib18","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2005.02.8464","article-title":"Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study","volume":"24","author":"Barakat","year":"2006","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104881_bib19","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ejca.2014.03.006","article-title":"Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis","volume":"50","author":"Shim","year":"2014","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104881_bib20","article-title":"Hormone replacement therapy for women previously treated for endometrial cancer","volume":"5","author":"Edey","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"issue":"14","key":"10.1016\/j.ijgc.2026.104881_bib21","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.3390\/jcm10143165","article-title":"Hormone replacement therapy in endometrial cancer survivors: a meta-analysis","volume":"10","author":"Londero","year":"2021","journal-title":"J Clin Med"},{"issue":"35","key":"10.1016\/j.ijgc.2026.104881_bib22","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.2015.60.9719","article-title":"Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial","volume":"33","author":"Eeles","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104881_bib23","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<1013::AID-CNCR17>3.0.CO;2-1","article-title":"Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial","volume":"86","author":"Guidozzi","year":"1999","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104881_bib24","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3390\/cancers15020356","article-title":"Impact of hormone replacement therapy on the overall survival and progression free survival of ovarian cancer patients: a systematic review and meta-analysis","volume":"15","author":"Achima\u015f-Cadariu","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104881_bib25","article-title":"Hormone replacement therapy after surgery for epithelial ovarian cancer","volume":"1","author":"Saeaib","year":"2020","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.ijgc.2026.104881_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.maturitas.2024.108004","article-title":"Hormone replacement therapy in women with iatrogenic premature ovarian insufficiency after radiotherapy for cervical cancer: a retrospective cohort and survey study","volume":"185","author":"Van der Hoef","year":"2024","journal-title":"Maturitas"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104881_bib27","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/20533691211028518","article-title":"Safety of hormone replacement therapy in women with a history of cervical adenocarcinoma","volume":"27","author":"Richardson","year":"2021","journal-title":"Post Reprod Health"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104881_bib28","article-title":"Hormone replacement therapy in gynecologic cancer: oncologic safety and alternative therapies","volume":"36","author":"Luzarraga","year":"2025","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104881_bib29","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.fertnstert.2024.11.007","article-title":"Evidence-based guideline: premature ovarian insufficiency","volume":"123","author":"ESHRE","year":"2025","journal-title":"Fertil Steril"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104881_bib30","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1056\/NEJMcp0808697","article-title":"Clinical practice. Primary ovarian insufficiency","volume":"360","author":"Nelson","year":"2009","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104881_bib31","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1097\/AOG.0000000000002044","article-title":"698: hormone therapy in primary ovarian insufficiency","volume":"129","year":"2017","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ijgc.2026.104881_bib32","unstructured":"National Comprehensive Cancer Network. Survivorship; Updated 2026-03-24. https:\/\/doi.org\/10.6004\/jncn.2026.0039."},{"issue":"9","key":"10.1016\/j.ijgc.2026.104881_bib33","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/jjco\/hyaf092","article-title":"Hormone replacement therapy in female-specific cancer survivors: considerations beyond cancer cure","volume":"55","author":"Yoshihama","year":"2025","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104881_bib34","first-page":"180","article-title":"Plasma levels of estrogen, luteinizing hormone, and follicle stimulating hormone following castration and estradiol implant","volume":"49","author":"Hunter","year":"1977","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ijgc.2026.104881_bib35","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.ijrobp.2024.10.023","article-title":"Improving treatment of radiation-induced premature ovarian insufficiency after cervical cancer: a practice quality improvement initiative","volume":"121","author":"Pepin","year":"2024","journal-title":"Int J Radiat Oncol"},{"issue":"32","key":"10.1016\/j.ijgc.2026.104881_bib36","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000043726","article-title":"Changes of hormone levels for postmenopausal women after bilateral oophorectomy: a meta-analysis","volume":"104","author":"Wu","year":"2025","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104881_bib37","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.maturitas.2015.07.006","article-title":"Treatment of climacteric symptoms in survivors of gynaecological cancer","volume":"82","author":"Biglia","year":"2015","journal-title":"Maturitas"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104881_bib38","doi-asserted-by":"crossref","first-page":"G49","DOI":"10.1093\/ejendo\/lvaf206","article-title":"European society of endocrinology clinical practice guideline for evaluation and management of menopause and the perimenopause","volume":"193","author":"Lumsden","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ijgc.2026.104881_bib39","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1477-7525-2-45","article-title":"The Menopause Rating Scale (MRS) scale: a methodological review","volume":"2","author":"Heinemann","year":"2004","journal-title":"Health Qual Life Outcomes"},{"issue":"1-2","key":"10.1016\/j.ijgc.2026.104881_bib40","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.maturitas.2008.09.014","article-title":"A menopause-specific Quality of Life Questionnaire: development and psychometric properties","volume":"61","author":"Hilditch","year":"2008","journal-title":"Maturitas"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104881_bib41","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0022-3999(76)90005-2","article-title":"A factor analytic study of climacteric symptoms","volume":"20","author":"Greene","year":"1976","journal-title":"J Psychosom Res"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104881_bib42","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/GME.0000000000000321","article-title":"Structural validity of a 16-item abridged version of the Cervantes Health-Related Quality of Life scale for menopause: the Cervantes Short-Form Scale","volume":"22","author":"Coronado","year":"2015","journal-title":"Menopause"},{"key":"10.1016\/j.ijgc.2026.104881_bib43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.maturitas.2018.11.012","article-title":"A comparison of quality of life and resilience in menopausal women with and without a history of gynaecological cancer","volume":"120","author":"Oliva","year":"2019","journal-title":"Maturitas"},{"key":"10.1016\/j.ijgc.2026.104881_bib44","doi-asserted-by":"crossref","unstructured":"Bunnewell S, Keating S, Parsons J, Hickey M, Hillman S. Women\u2019s and health care professionals\u2019 experiences of discontinuing hormone replacement therapy (HRT): a systematic review. BJOG. Published online September 26, 2025. doi:10.1111\/1471-0528.70023.","DOI":"10.1111\/1471-0528.70023"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104881_bib45","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMcp1714787","article-title":"Hormone therapy for postmenopausal women","volume":"382","author":"Pinkerton","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104881_bib46","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/01.AOG.0000441353.20693.78","article-title":"ACOG practice bulletin no. 141: management of menopausal symptoms","volume":"123","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104881_bib47","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMcp2116488","article-title":"Primary ovarian insufficiency","volume":"388","author":"Stuenkel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijgc.2026.104881_bib48","unstructured":"US Food and Drug Administration. stradiol Trans-dermal System: Prescribing Information. Silver Spring (MD): U.S. Food and Drug Administration. updated 2026 https:\/\/download.open.fda.gov\/drug\/label\/drug-label-0012-0f-0014.json.zip."},{"issue":"15","key":"10.1016\/j.ijgc.2026.104881_bib49","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJMra2202438","article-title":"Sex hormone influences on venous thrombotic and cardiovascular risk","volume":"394","author":"Skeith","year":"2026","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104881_bib50","article-title":"Hormone therapy in postmenopausal women and risk of endometrial hyperplasia or endometrial cancer","volume":"10","author":"Kim","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104881_bib51","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1210\/jcem.87.1.8141","article-title":"Tibolone for postmenopausal women: systematic review of randomized trials","volume":"87","author":"Modelska","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104881_bib52","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/ijgc-2019-001034","article-title":"Vaginal estrogen use for genitourinary symptoms in women with a history of uterine, cervical, or ovarian carcinoma","volume":"30","author":"Chambers","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104881_bib53","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/AOG.0000000000004601","article-title":"Treatment of urogenital symptoms in individuals with a history of estrogen-dependent breast cancer: clinical consensus","volume":"138","year":"2021","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ijgc.2026.104881_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.maturitas.2026.108914","article-title":"Safety of vaginal estrogen in breast cancer survivors: current evidence on systemic absorption and oncologic outcomes","volume":"208","author":"Mainar","year":"2026","journal-title":"Maturitas"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104881_bib55","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.7326\/ANNALS-24-00610","article-title":"Hormonal treatments and vaginal moisturizers for genitourinary syndrome of menopause: a systematic review","volume":"177","author":"Danan","year":"2024","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijgc.2026.104881_bib56","unstructured":"Cancer drug interactions. Radboud University Medical Center, University of Liverpool. Accessed July 4, 2026. https:\/\/www.cancer-druginteractions.org."},{"issue":"15","key":"10.1016\/j.ijgc.2026.104881_bib57","doi-asserted-by":"crossref","first-page":"e811","DOI":"10.1161\/CIR.0000000000001056","article-title":"Cardio-oncology drug interactions: a scientific statement from the American Heart Association","volume":"145","author":"Beavers","year":"2022","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104881_bib58","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.3324\/haematol.2023.284778","article-title":"Targeted anti-cancer agents and risk of venous thromboembolism","volume":"109","author":"Verso","year":"2024","journal-title":"Haematologica"},{"issue":"1-2","key":"10.1016\/j.ijgc.2026.104881_bib59","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.seminoncol.2023.09.005","article-title":"PARP inhibitors: a review of the pharmacology, pharmacokinetics, and pharmacogenetics","volume":"51","author":"Zeng","year":"2024","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ijgc.2026.104881_bib60","series-title":"Zejula (niraparib): EPAR - product Information [Internet]","year":"2025"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104881_bib61","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104881_bib62","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1210\/clinem\/dgac689","article-title":"Approach to the patient with immune checkpoint inhibitor-associated endocrine dysfunction","volume":"108","author":"Wright","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"36","key":"10.1016\/j.ijgc.2026.104881_bib63","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104881_bib64","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/AOG.0000000000005812","article-title":"Fezolinetant and elinzanetant therapy for menopausal women experiencing vasomotor symptoms: a systematic review and meta-analysis","volume":"145","author":"Menegaz De Almeida","year":"2025","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104881_bib65","first-page":"173","article-title":"The efficacy and safety of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors in the treatment of menopausal hot flashes: a systematic review of clinical trials","volume":"47","author":"Azizi","year":"2022","journal-title":"Iran J Med Sci"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104881_bib66","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1001\/jamainternmed.2014.1891","article-title":"Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial","volume":"174","author":"Joffe","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104881_bib67","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1111\/1471-0528.13951","article-title":"Effect and safety of paroxetine for vasomotor symptoms: systematic review and meta-analysis","volume":"123","author":"Wei","year":"2016","journal-title":"BJOG"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104881_bib68","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1097\/GME.0000000000000546","article-title":"\u2018Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of the North American Menopause Society","volume":"22","year":"2015","journal-title":"Menopause"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104881_bib69","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1097\/GME.0000000000000773","article-title":"Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial","volume":"23","author":"Simon","year":"2016","journal-title":"Menopause"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104881_bib70","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1470-2045(11)70364-3","article-title":"Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial","volume":"13","author":"Mann","year":"2012","journal-title":"Lancet Oncol"},{"issue":"31","key":"10.1016\/j.ijgc.2026.104881_bib71","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1200\/JCO.2008.16.6389","article-title":"Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors","volume":"26","author":"Elkins","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104881_bib72","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jamainternmed.2018.0116","article-title":"Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: a randomized clinical trial","volume":"178","author":"Mitchell","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"30","key":"10.1016\/j.ijgc.2026.104881_bib73","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.2014.60.7366","article-title":"A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial","volume":"33","author":"Goetsch","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104881_bib74","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/JU.0000000000004589","article-title":"The AUA\/SUFU\/AUGS guideline on genitourinary syndrome of menopause","volume":"214","author":"Kaufman","year":"2025","journal-title":"J Urol"},{"key":"10.1016\/j.ijgc.2026.104881_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.maturitas.2022.08.013","article-title":"Vaginal laser therapy versus hyaluronic acid suppositories for women with symptoms of urogenital atrophy after treatment for breast cancer: a randomized controlled trial","volume":"167","author":"Gold","year":"2023","journal-title":"Maturitas"},{"key":"10.1016\/j.ijgc.2026.104881_bib76","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejogrb.2022.08.012","article-title":"Fractional Co2 laser for vulvo-vaginal atrophy in gynecologic cancer patients: a valid therapeutic choice? A systematic review","volume":"277","author":"D\u2019Oria","year":"2022","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104881_bib77","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician\u2019s guide to prevention and treatment of osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos Int."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26004123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26004123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:33:46Z","timestamp":1794000826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26004123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":77,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1048891X26004123"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104881","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hormone replacement therapy in gynecologic cancer survivors: bridging the gap between evidence and clinical practice","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104881","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104881"}}